SCHEMBL19979324

SCHEMBL19979324

COCCOCCSCCCNC(=O)c1ncn2c(=O)n(C)nnc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.51
CA1 P00915 3/20 0.51
CA2 P00918 3/20 0.51
CA9 Q16790 3/20 0.51
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PABPC1 P11940 1/20 0.47
LMNA P02545 3/20 0.33
THRB P10828 2/20 0.33
ALDH1A1 P00352 5/20 0.32
NR3C1 P04150 1/20 0.32
HPGD P15428 2/20 0.31
HSD17B10 Q99714 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
RXFP1 Q9HBX9 2/20 0.31
KDM4E B2RXH2 2/20 0.31
MAPT P10636 1/20 0.30
PKM P14618 1/20 0.30
HTT P42858 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21974446 0.80 CA12 (0.47) CA12CA1CA2CA9MEN1
SCHEMBL19979304 0.79 MEN1 (0.50) CA12CA1CA2CA9MEN1
Hydrochloric Acid SCHEMBL30938537 0.73 MEN1 (0.48) CA12CA1CA2CA9MEN1
SCHEMBL16569258 0.73 MEN1 (0.61) CA12CA1CA2CA9MEN1
SCHEMBL21711170 0.73 MEN1 (0.61) CA12CA1CA2CA9MEN1
SCHEMBL19984435 0.72 CA12 (0.61) CA12CA1CA2CA9MEN1
SCHEMBL19984431 0.72 CA12 (0.58) CA12CA1CA2CA9MEN1
SCHEMBL15788844 0.72 KMT2A (0.72) CA12CA1CA2CA9MEN1
SCHEMBL3859207 0.71 MEN1 (0.69) CA12CA1CA2CA9MEN1
SCHEMBL7876576 0.71 MEN1 (0.69) CA12CA1CA2CA9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912709-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease UNIVERSITY OF MASSACHUSETTS (US) 2024-02-27 US disclosed
US-11912709-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease UNIVERSITY OF MASSACHUSETTS (US) 2024-02-27 US disclosed
US-20180079754-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE NATIONAL SCIENCE FOUNDATION 2018-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912709-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease PBRM1, MGMT, TOP1 CA12 2243/4885CA1 2340/4885CA2 4763/4885
US-20180079754-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE PBRM1, MGMT, TOP1 CA12 2243/4885CA1 2340/4885CA2 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.